Complicated Intra-Abdominal Infection Clinical Trial
Official title:
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Verified date | August 2017 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Status | Completed |
Enrollment | 493 |
Est. completion date | April 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - 18 to 90 years of age inclusive - Female patient is authorized to participate if at least one of the following criteria are met: 1. Surgical sterilization 2. Age =50 years and postmenopausal as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments 3. Age <50 years and postmenopausal as defined by documented LH and FSH levels in the postmenopausal range PLUS amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments 4. Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin [ß-hCG]) within 1 day prior to study entry, and agrees to use highly effective contraception methods during treatment and for at least 7 days after last dose of IV study therapy - Intraoperative/postoperative enrollment with confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis - Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory response; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections Exclusion Criteria: - Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious - Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation - Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis - Patient is considered unlikely to survive the 6 to 8 week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality |
Country | Name | City | State |
---|---|---|---|
Argentina | Research Site | Córdoba | |
Argentina | Research Site | Rosario | |
Bulgaria | Research Site | Ruse | |
Bulgaria | Research Site | Varna | |
Croatia | Research Site | Zagreb | |
Czechia | Research Site | Decin | |
Czechia | Research Site | Hradec Kralove | |
Czechia | Research Site | Jihlava | |
Czechia | Research Site | Olomouc | |
Czechia | Research Site | Praha 10 | |
Czechia | Research Site | Praha 5 | |
Czechia | Research Site | Teplice | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Székesfehérvár | |
India | Research Site | Bangalore | |
India | Research Site | Pune | |
India | Research Site | Trivandrum | |
India | Research Site | Vadodara | |
Israel | Research Site | Hadera | |
Israel | Research Site | Haifa | |
Latvia | Research Site | Riga | |
Malaysia | Research Site | Alor Setar | |
Mexico | Research Site | Durango | |
Mexico | Research Site | Guadalajara, Jalisco | |
Mexico | Research Site | Mexico City | |
Netherlands | Research Site | Enschede | |
Netherlands | Research Site | s-Hertogenbosch | |
Peru | Research Site | Arequipa | |
Peru | Research Site | Cercardo de Lima | |
Peru | Research Site | Lima | |
Peru | Research Site | Trujillo | |
Romania | Research Site | Cluj-Napoca | |
Romania | Research Site | Iasi | |
Russian Federation | Research Site | Kemerovo | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Saratov | |
Russian Federation | Research Site | Vsevolozhsk | |
South Africa | Research Site | Pretoria | |
Spain | Research Site | Alcorcón | |
Spain | Research Site | Elche | |
Spain | Research Site | Sabadell(Barcelona) | |
Taiwan | Research Site | Kaohsiung | |
Taiwan | Research Site | Taichung | |
Taiwan | Research Site | Tainan | |
Taiwan | Research Site | Taipei | |
Thailand | Research Site | Bangkok | |
Thailand | Research Site | Khon Kaen | |
Thailand | Research Site | Phisanulok | |
Ukraine | Research Site | Dnipropetrovsk | |
Ukraine | Research Site | Ivano-Frankivsk | |
Ukraine | Research Site | Kharkov | |
Ukraine | Research Site | Kyiv | |
Ukraine | Research Site | Zaporizhzhya | |
United States | Research Site | Chula Vista | California |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | San Diego | California |
United States | Research Site | Somers Point | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Pfizer | Forest Laboratories |
United States, Argentina, Bulgaria, Croatia, Czechia, Hungary, India, Israel, Latvia, Malaysia, Mexico, Netherlands, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Thailand, Ukraine,
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA). | The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA. | TOC: 28 to 35 days after start of study drug | |
Primary | Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]). | The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. | TOC: 28 to 35 days after start of study drug | |
Primary | Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]). | The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. | TOC: 28 to 35 days after start of study drug | |
Secondary | Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set | The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. | TOC: 28 to 35 days after start of study drug | |
Secondary | Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set | The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. | TOC: 28 to 35 days after start of study drug | |
Secondary | Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT) | Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. | EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug | |
Secondary | Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set | Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence). | EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug | |
Secondary | Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set. | The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. | TOC: 28 to 35 days after start of study drug. | |
Secondary | Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set | Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. | Test of Cure: 28 to 35 days after start of study drug | |
Secondary | Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set | The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. | TOC: 28 to 35 days after start of study drug | |
Secondary | Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set | Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence). | Test of Cure: 28 to 35 days after start of study drug | |
Secondary | Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry | Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (=37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. | Test of Cure: 1 to 14 days after start of study drug | |
Secondary | Plasma Concentrations for Ceftazidime and Avibactam | Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations | Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
Completed |
NCT03293485 -
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
|
Phase 3 | |
Recruiting |
NCT05148702 -
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
|
Phase 3 | |
Completed |
NCT04927312 -
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
|
Phase 3 | |
Completed |
NCT00929643 -
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
|
N/A | |
Completed |
NCT01147640 -
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
|
Phase 2 | |
Completed |
NCT01644643 -
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
|
Phase 3 | |
Completed |
NCT01726023 -
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
|
Phase 3 | |
Withdrawn |
NCT01602874 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT01265784 -
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
|
Phase 2 | |
Withdrawn |
NCT00914888 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00157898 -
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
|
Phase 4 | |
Recruiting |
NCT05733104 -
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
|
||
Completed |
NCT01445678 -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
|
Phase 3 | |
Completed |
NCT02739997 -
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
|
Phase 3 | |
Completed |
NCT03329092 -
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
|
Phase 3 | |
Completed |
NCT03217136 -
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
|
Phase 2 | |
Completed |
NCT01500239 -
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
|
Phase 3 |